Stifel Financial
SPRO icon

Stifel Financial’s Spero Therapeutics SPRO Stock Holding History

Stifel Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,766
Closed -$18.6K – 3416
2022
Q4 		$18.6K Sell
10,766
-1,740
-14% -$3.25K ﹤0.01% 3249
2022
Q3 		$25K Sell
12,506
-13,722
-52% -$13.6K ﹤0.01% 3222
2022
Q2 		$19K Sell
26,228
-11,500
-30% -$33.4K ﹤0.01% 3282
2022
Q1 		$328K Buy
37,728
+7,842
+26% +$80.3K ﹤0.01% 2827
2021
Q4 		$479K Sell
29,886
-17,430
-37% -$277K ﹤0.01% 2612
2021
Q3 		$871K Sell
47,316
-1,753
-4% -$28.1K ﹤0.01% 2203
2021
Q2 		$685K Buy
49,069
+500
+1% +$6.99K ﹤0.01% 2389
2021
Q1 		$714K Sell
48,569
-419
-0.9% -$7.37K ﹤0.01% 2237
2020
Q4 		$950K Sell
48,988
-1,280
-3% -$20K ﹤0.01% 1883
2020
Q3 		$561K Buy
50,268
+7,481
+17% +$88.5K ﹤0.01% 2011
2020
Q2 		$579K Sell
42,787
-1,209
-3% -$13.6K ﹤0.01% 1941
2020
Q1 		$355K Buy
43,996
+13,969
+47% +$123K ﹤0.01% 2081
2019
Q4 		$289K Buy
30,027
+17,078
+132% +$184K ﹤0.01% 2548
2019
Q3 		$137K Buy
+12,949
New +$136K ﹤0.01% 2726

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial's SPRO Position: Q1 2023 in Review

Stifel Financial sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 10,766 shares — an estimated $18.6K sold.

Stifel Financial first reported a position in SPRO in Q3 2019 and held it in 14 quarters. The position peaked at $950K in Q4 2020. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

  • Stifel Financial reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Stifel Financial sold 10,766 Spero Therapeutics shares in Q1 2023, an estimated $18.6K.
  • Stifel Financial first reported a position in Spero Therapeutics in Q3 2019 and held it in 14 quarters.
  • Stifel Financial's Spero Therapeutics position peaked at $950K in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Stifel Financial's 13F filing for Q1 2023, filed 12 May 2023.